Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Mons – page 36

640 clinical trials in Mons, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mons at a glance
640
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

640 trials in Mons

Open in trial search

Study of QEL-001 (CAR T regulatory cell therapy) to prevent liver transplant rejection in patients with HLA-A2 positive donor organ

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:QEL-001
  • Sponsor:Quell Therapeutics Limited

Septic shock

Not recruiting

Study on Nicotinamide for Preventing Kidney Problems in Septic Shock Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nicotinamide
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Study of ICT01 and Pembrolizumab for Patients with Advanced-Stage, Relapsed/Refractory Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ICT01
  • Sponsor:Imcheck Therapeutics

Breast cancer female

Not recruiting

Study on Chemotherapy and Hormone Therapy for Women Over 70 with ER-Positive, HER2-Negative Breast Cancer Using Cyclophosphamide and Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Unicancer

Study on Inupadenant, Carboplatin, and Pemetrexed for Adults with Metastatic Non-Small Cell Lung Cancer After Immunotherapy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Inupadenant Hydrochloride
  • Sponsor:iTeos Belgium

Study on the Effects of IO102 Hydrochloride and IO103 Acetate for Patients with Head and Neck Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:IO102 hydrochloride
  • Sponsor:Cliniques Universitaires Saint-Luc

Study on the Effects of Sparsentan and Irbesartan for Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Irbesartan
  • Sponsor:Travere Therapeutics Inc.

Colorectal cancer

Not recruiting

Study of Nivolumab, Ipilimumab, Relatlimab, and Daratumumab in Patients with Recurrent and Metastatic Colon Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Bristol Myers Squibb International Corporation

Study on the Safety and Effectiveness of Mitazalimab with Chemotherapy for Patients with Metastatic Pancreatic Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Alligator Bioscience AB

Study on Mepolizumab and Drug Combination for Patients with Eosinophilic Granulomatosis with Polyangiitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Assistance Publique Hopitaux De Paris

Study on the Effect of Cemiplimab in Patients with Oligometastatic Non-Small Cell Lung Cancer After Radical Treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Bladder cancer

Not recruiting

Study of Atezolizumab with BCG Treatment for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Previously Received BCG

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Atezolizumab
  • Sponsor:Unicancer

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Mons

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on lung cancer treatments, including studies of combination therapies with BNT327 and investigations into both small cell and non-small cell variants. Additional research covers breast cancer and cervical cancer treatments.

  • Non-small cell lung cancer therapy optimization
  • Advanced solid tumors treatment
  • Lymphoma treatment innovations

Studies aim to improve survival rates and treatment effectiveness through targeted therapies and immunotherapy combinations.

02 Cardiovascular Studies

Comprehensive research into coronary artery disease and post-stroke treatments, evaluating new antiplatelet therapies and innovative stent technologies. Studies focus on reducing cardiovascular events and improving patient outcomes.

  • Acute coronary syndrome management
  • Stroke prevention strategies
  • Antiplatelet therapy optimization

Investigations aim to enhance treatment protocols and reduce cardiovascular complications.

03 Autoimmune Conditions

Groundbreaking research in multiple sclerosis and psoriatic arthritis treatments, evaluating novel therapeutic approaches including BTK inhibitors and biological treatments.

  • Progressive MS treatment development
  • Arthritis management innovations
  • Long-term therapy effectiveness

Focus on improving quality of life and disease management for patients with chronic autoimmune conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.